09.19.2020
Other
$150,449.00
18 months
Leveraging single-cell genomics to understand the interplay between biologic treatments of inflammatory diseases and COVID-19 disease
IBD patients, especially those receiving anti-inflammatory biologic therapy, are considered high-risk for SARS-CoV-2 infection, but a thorough investigation into how the immune system responds to the virus in the presence of biologic therapy has not yet been performed. This study will provide an understanding of the development of protective immune responses against SARS-CoV-2 in IBD patients and provide insight into the specific mechanisms involved.